#1
|
|||
|
|||
Ðåéíî
Íå ìîã ïðîéòè ìèìî:
http://forums.rusmedserv.com/showthread.php?t=106290 Òàê âñå-òàêè, ñèíäðîì Ðåéíî, áîëåçíü Ðåéíî, ôåíîìåí Ðåéíî, ïåðâè÷íûé Ðåéíî, âòîðè÷íûé Ðåéíî? Êòî êàêîé êëàññèôèêàöèåé ïîëüçóåòñÿ? Åñëè íåò êëàññè÷åñêèõ òðåõ öâåòîâ, òî âñå ðàâíî Ðåéíî? Êàê âëèÿåò íà äèàãíîç, âñå ëè ïàëüöû âîâëå÷åíû? |
#2
|
|||
|
|||
Öèòàòà:
Âòîðè÷íûé ñèíäðîì (ôåíîìåí) Ðåéíî "Ôðàíöóçñêèé òðèêîëîð" íå îáÿçàòåëåí, ïîáëåäíåíèå - íàèáîëåå õàðàêòåðíûé ïðèçíàê Ïîñëåäíèé âîïðîñ íå ñîâñåì ïîíÿëà, íî â ïðåäåëàõ ñâîåãî ïîíèìàíèÿ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Öèòàòà:
Öèòàòà:
__________________
Ñ óâàæåíèåì |
#3
|
|||
|
|||
Ó ìåíÿ ñëîæèëîñü îùóùåíèå ÷òî ñ Ðåéíî î÷åíü ìíîãî ýìïèðèêè (÷òîáû íå ñêàçàòü ïóòàíèöû).
- Íåêîòîðûå íåìåöêèå êîëëåãè óòâåðæäàþò, ÷òî ïðè ïåðâè÷íîì Ðåéíî, êàê ïðàâèëî, íå ïîðàæàþòñÿ áîëüøèå ïàëüöû (ê ñîæàëåíèþ, áåç óêàçàíèÿ èñòî÷íèêà èíôîðìàöèè - ïîòîìó è âûíîøó ýòî íà îáñóæäåíèå). - Ó æåíùèí ïåðâè÷íûé Ðåéíî ãîðàçäî ÷àùå (êòî áû ìíå ñêàçàë, êàêîé ó ýòîãî ìåõàíèçì?). - "Òðèêîëîð íå îáÿçàòåëåí, äîñòàòî÷íî ïîáåëåíèÿ" - òîæå âîïðîñ, îòêóäà ýòî? Ãàéäëàéíû? À åñëè ïîñèíåíèå, à íå ïîáåëåíèå (áûëè è òàêèå ïàöèåíêè)? - Íàñêîëüêî âëèÿåò íà äèàãíîç ñêîðîñòü ïîáåëåíèÿ/ïîñèíåíèÿ? ×àñòü êîëëåã (è îïÿòü áåç ññûëêè ) Óòâåðæäàåò, ÷òî "ñ÷èòàåòñÿ" òîëüêî áûñòðîå (< íåñêîëüêèõ ìèíóò) èçìåíåíèå öâåòà. - ×òî ñ÷èòàòü ïàòîëîãèåé â êàïèëëÿðíîé ìèêðîñêîïèåé, à ÷òî íîðìîé (ñ êðàéíèìè ñëó÷àÿìè ïîíÿòíî, à âîò ãäå ïðîâåñòè ãðàíèöó)?  Ðîññèè ýòîò ìåòîä èñïîëüçóåòñÿ (âî âðåìÿ îáó÷åíèÿ â Ïèòåðå íè ðàçó íå ñòàëêèâàëñÿ )? - "Anti-nuclear antibody tests are negative." Ýòî âñå, ÷òî èç ñåðîëîãèè ïîëîæåíî äåëàòü? - Ïîíÿòíî, ÷òî ïðè ïåðâè÷íîì Ðåéíî - ïðîñòî "èíäèâèäóàëüíûå îñîáåííîñòè, ïîâûøåííàÿ ðåàêòèâíîñòü ñîñóäîâ". À íà ìîëåêóëÿðíîì óðîâíå? |
#4
|
||||
|
||||
Öèòàòà:
Vasc Med. 2005 Nov;10(4):293-307. Mechanisms of Raynaud's disease. Cooke JP, Marshall JM. Section of Vascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305-5406, USA. Raynaud's phenomenon is due to transient cessation of blood flow to the digits of the hands or feet. An attack of Raynaud's phenomenon is classically manifested as triphasic color changes. The white phase is due to excessive vasoconstriction and cessation of regional blood flow. This phase is followed by a cyanotic phase, as the residual blood in the finger desaturates. The red phase is due to hyperemia as the attack subsides and blood flow is restored. An attack is frequently associated with pain and/or paresthesia due to sensory nerve ischemia. Variants of Raynaud's phenomenon include acrocyanosis and primary livedo reticularis, each of which is associated with reduced skin blood flow, exacerbated by cold or emotional upset. Raynaud's phenomenon in the absence of other disorders is primary Raynaud's phenomenon, or Raynaud's disease. The mechanisms of Raynaud's disease include increased activation of the sympathetic nerves, in response to cold or emotion; an impaired habituation of the cardiovascular response to stress may contribute. In addition, there appears to be a local fault, which is likely multifactorial. This local fault is due to an alteration in vascular function rather than vascular structure. The alteration in vascular function may be related to increased sensitivity to cold of the adrenergic receptors on the digital artery vascular smooth muscle. In some cases, locally released or systemically circulating vasoconstrictors may participate, including endothelin, 5-hydroxytryptamine and thromboxane. A deficiency or increased degradation of nitric oxide, possibly due to increased oxidative stress, may be involved in some cases. These recent pathophysiological insights may lead to new therapeutic options. --- Hautarzt. 2006 Sep;57(9):819-28. [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach] [Article in German] Sunderkötter C, Riemekasten G. Klinik und Poliklinik für Dermatologie, Universitätsklinikum Münster, Von-Esmarch-Strasse 58, 48129 Münster. Raynaud phenomenon (RP) is characterized by recurrent spasms of small digital arterioles/arteries at fingers and toes, usually triggered by cold and emotional stress. Clinically a sudden pallor of individual digits is followed by reactive hyperemia, in severe cases also by cyanosis. One distinguishes between primary RP, i.e. RP without an underlying disease or drug intake, and secondary RP, which is causally related to an underlying disease or to intake of certain drugs (e.g. interferon, cisplatin). Primary RP is frequent (prevalence of about 13-20% in northern or central Europe), while secondary RP is rare, but the major presenting symptom for systemic sclerosis (SSc). Differential diagnosis includes cold-induced pallor, acute embolic events, paroxysmal hematoma of the finger or erythromelalgia. Vasoconstrictive mechanisms outweigh vasodilatory ones in endothelial cells and vascular smooth muscle. Although soluble mediators such as endothelin or certain prostaglandins have been exploited successfully for therapy, the extent of their involvement in the initial pathophysiology of RP is unclear. Secondary RP (associated with SSc) additionally features morphological alterations with compromise of the vessel lumen. As RP can result in severe discomfort and complications, timely diagnosis and treatment is essential.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#5
|
||||
|
||||
Ñ ó÷åòîì Âàøåãî ïðåäûäóøåãî íàó÷íîãî îïûòà áûòü ìîæåò áóäåò èíòåðåñíûì åòîò íåäàâíèé îáçîð:
Autoimmun Rev. 2009 Aug 15. Homocysteine and Raynaud's phenomenon: A review. Lazzerini PE, Capecchi PL, Bisogno S, Cozzalupi M, Rossi PC, Pasini FL. Department of Clinical Medicine and Immunological Sciences, University of Siena, Italy. Raynaud's phenomenon, categorized as primary and secondary when occurring isolated or in association with an underlying disease, respectively, is a paroxysmal and recurrent acral ischemia resulting from an abnormal arterial vasospastic response to cold or emotional stress. The key issue in the pathogenesis of Raynaud's phenomenon is presumed to be a dysregulation in the mechanisms of vascular motility resulting in an imbalance between vasodilatation and vasoconstriction. Homocysteine, a non-protein forming sulphured amino acid proposed as an independent risk factor for atherothrombosis in the general population, clearly demonstrated to produce vascular damage through mechanisms also including endothelial injury and modifications in circulating mediators of vasomotion. The rationale for homocysteine involvement in the pathogenesis of Raynaud's phenomenon led some authors to investigate the possible association between mild hyperhomocysteinemia and such a vascular disturbance, particularly in the course of connective tissue disease. Here we review data regarding this putative association and the supposed mechanisms involved, also discussing the emblematic case of a patient with new-onset severe Raynaud's phenomenon and markedly elevated homocysteinemia.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#6
|
|||||
|
|||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
 Ðîññèè êàïèëëÿðîñêîïèþ äåëàþò, êîíå÷íî, íå ðóòèííàÿ ïðàêòèêà, íî â Ìîñêâå çíàþ, ïî êðàéíåé ìåðå, 2 ÷àñòíûõ öåíòðà, ãäå ýòî äåëàþò Öèòàòà:
äâå áàçîâûå òåîðèè: Ëåâè: ïîâûøåííàÿ ÷óâñòâèòåëüíîñòü ê àëüôà-àäðåíåðãè÷åñêîé ñòèìóëÿöèè, äåôèöèò êàëüöèòîíèí-ãåí-ñâÿçàííîãî ïåïòèäà, âûñîêàÿ êîíöåíòðàöèÿ ýíäîòåëèíà, Ðåéíî: ãèïåðàêòèâíîñòü ñèìïàòè÷åñêîé íåðâíîé ñèñòåìû Êñòàòè, à ïî÷åìó Âû ïðåäúÿâëÿåòå òîëüêî ãîëîñëîâíûå óòâåðæäåíèÿ, ó íàñ íà ôîðóìå ïðèíÿòî ññûëêè ïðåäîñòàâëÿòü À òî ìû Âàì èíôîðìàöèþ, à ÷òî âçàìåí? Âîïðîñû çàäàåòå, à íà íàøè íå îòâå÷àåòå
__________________
Ñ óâàæåíèåì |
#7
|
|||
|
|||
Ñïàñèáî
 äðóãèõ òåìàõ, ãäå çíàë, ïðåäîñòàâëÿë ññûëêè. Ãäå íå çíàþ, ÷åñòíî ýòî ïðèçíàþ. Íà ñàìîì äåëå, çàäóìàëñÿ íàä ôèëîñîôñêèì âîïðîñîì, êàêèìè êðèòåðèÿìè ðóêîâîäñòâîâàòüñÿ ïðè îòêðûòèè íîâîé òåìû íà ôîðóìå (Ýòî ÿ âñå îñâàèâàþñü ñ îñîáåííîñòè îíëàéíîâñêîãî ìåäèöèíñêîãî îáùåíèÿ). PubMed - îí ó âñåõ PubMed. Press release'û è òàê âñåì äîñòóïíû. ÈÌÕÎ: èíîãäà ìíîãî ãàéäëàéíîâ, èíòåðåñíî óçíàòü, êòî êàêîé äëÿ ñåáÿ âûáðàë èíîãäà ïî òåìå ìíîãî ïðîòèâîðå÷èâûõ ìíåíèé (êàê ñ òåì æå Ðåéíî), è õî÷åòñÿ óçíàòü, êàêîé ó êîëëåã ïðàêòè÷åñêèé îïûò â ýòîì âîïðîñå. èíîãäà óñëûøàë ÷òî-òî îò êîëëåã-ïðàêòèêîâ, à ññûëêè îíè ïðîñòî íå ïîìíèëè, èëè íå ñïðîñèë (ñïðîøó ïðè ñëó÷àå è íàïèøó ) èíîãäà íîâîñòü êàêàÿ-òî, íåâîçìîæíî æå ñëåäèòü çà âñåìè íîâîñòÿìè - êòî-òî âûëîæèë íîâîñòü, êîëëåãàì ïîëüçà íó è êàêîé-òî êîíêðåòíûé ñëó÷àé îáñóäèòü Ñîððè çà ôëóä. Òåïåðü ê Ðåéíî. Âû ïèøåòå, ÷òî êàïèëëÿðíàÿ ìèêðîñêîïèÿ åñòü òîëüêî â äâóõ ÷àñòíûõ öåíòðàõ. Ýòî ôèíàíñîâûé âîïðîñ èëè ñ÷èòàåòñÿ, ÷òî è áåç íåå ìîæíî îáîéòèñü?  Ðîññèè ïàöèåíòîâ ñ Ðåéíî âåäóò ðåâìàòîëîãè? Ó ìåíÿ áûë èíòåðåñíûé êëèíè÷åñêèé ñëó÷àé. Îáðàòèëñÿ çíàêîìûé (òîâàðèù ìîåãî êîëëåãè ïî âîëëåéáîëüíîé êîìàíäå). 40 ëåò. Ïîëãîäà íàçàä íà÷àëèñü ïîáåëåíèÿ ïàëüöåâ ïðàâîé ðóêè (â îñíîâíîì, ñðåäíåãî è áåçûìÿííîãî) ïðè ïåðåîõëàæäåíèè. Íåêðîçà, ÿçâ íå áûëî. Capillar microscopy íîðìà, erythrocyte sedimentation rate (ESR) íîðìà, anti-nuclear antibody tests - negative. Âàø äèàãíîç/ïëàí îáñëåäîâàíèÿ? |
|
#8
|
|||
|
|||
Öèòàòà:
Öèòàòà:
Öèòàòà:
__________________
Ñ óâàæåíèåì |
#9
|
|||
|
|||
Ñïàñèáî.
Ïîáåëåíèå ñîïðîâîæäàëîñü îùóùåíèåì îíåìåíèÿ. Íàðóøåíèÿ ÷óâñòâèòåëüíîñòè è áîëåé íå áûëî. Ñèíäðîì êàðïàëüíîãî êàíàëà îðòîïåäû èñêëþ÷èëè. Êóäà íàïðàâèòü äàëüíåéøèé äèàãíîñòè÷åñêèé ïîèñê? |
#10
|
|||
|
|||
Öèòàòà:
|
#11
|
|||
|
|||
Ïîêà ÷òî, äèàãíîç íèêòî íå ïèñàë
ß ïðåäñòàâèë êëèíè÷åñêèé ñëó÷àé, êîòîðûé ñ ìîåé òî÷êè çðåíèÿ íå ñîâñåì îáû÷íûé. Ìû ïîòîì â êëèíèêå ñîøëèñü íà äèàãíîçå, è ÿ â êîíöå åãî îçâó÷ó (è, ðàçóìååòñÿ, âîñïðèìó êðèòèêó, åñëè êîëëåãè íå ñîãëàñÿòñÿ ñ íàøåé èíòåðïðåòàöèåé), íî ïåðåä ýòèì õîòåë áû óçíàòü ìíåíèå êîëëåã. Ãîòîâ ïðåäîñòàâèòü âñþ íåîáõîäèìóþ èíôîðìàöèþ. Óâàæàåìûé LupusDoc, ïðàâèëüíî ëè ÿ ïîíèìàþ, ÷òî Âû óòâåðæäàåòå, ÷òî Ðåéíî íå ìîæåò áûòü òîëüêî íà îäíîé ðóêå? Äàæå âòîðè÷íûé? Ñóäÿ ïî öèòàòàì, êîòîðûå ïîìåñòèëà Þíîíà Õîìèöêàÿ ïðè âòîðè÷íîì Ðåéíî âïîëíå ìîæåò áûòü àññèìåòðè÷íîå ïîðàæåíèå. Ñ äðóãîé ñòîðîíû, Capillar microscopy íîðìà, erythrocyte sedimentation rate (ESR) íîðìà, anti-nuclear antibody tests - negative. Óâàæàåìûé LupusDoc, åñëè Âû ñ÷èòàåòå, ÷òî ýòî íå Ðåéíî, òî êàêèå äàëüíåéøèå òåñòû (èëè ñðàçó äèàãíîç?) Âû áû ïðåäëîæèëè? Óâàæàåìàÿ Þíîíà Õîìèöêàÿ, åñëè Âû ñîãëàñíû, ÷òî îïèñàííàÿ êëèíè÷åñêàÿ êàðòèíà óêëàäûâàåòñÿ â ñèíäðîì Ðåéíî, òî êàê òîãäà ðåøèòü, ïåðâè÷íûé è âòîðè÷íûé? Êàêèå äàëüíåéøèå òåñòû (èëè ñðàçó äèàãíîç?) Âû áû ïðåäëîæèëè? |
#12
|
|||
|
|||
__________________
Ñ óâàæåíèåì |
#13
|
|||
|
|||
Ðåíòãåí áåç ïàòîëîãèé. À ïî÷åìó íå ñîãëàñíû? Ïîáåëåíèå, âûçâàííîå õîëîäîì. Âû æå ñàìè ïèñàëè, ÷òî íå îáÿçàòåëüíî äîëæåí áûòü "òðèêîëîð"
|
#14
|
|||
|
|||
ïåðâè÷íûé Ðåéíî âñåãäà ñèììåòðè÷íûé, òî åñòü ïîðàæàåò îáå ðóêè
__________________
Ñ óâàæåíèåì |
#15
|
|||
|
|||
Âû íàïèñàëè âûøå, ÷òî ñèíäðîì Ðåéíî áûâàåò íå òîëüêî ïåðâè÷íûé, íî è âòîðè÷íûé, ïðè êîòîðîì âîçìîæíî àññèìåòðè÷íîå ïîðàæåíèå. Òîãäà, ïî÷åìó ýòî íå Ðåéíî? Êàêîé òîãäà Âàø äèàãíîç (åñëè íåäîñòàòî÷íî èíôîðìàöèè, ñïðàøèâàéòå)?
|